Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation

Renato Zambello, Laura Bonaldi, Tamara Berno, Annalisa Martines, Erica Sechettin, Elena De March, Antonio Branca, Albana Lico, Claudia Minotto, Chiara Briani, Carmela Gurrieri, Francesca Temporin, Claudia Battistutta, Francesco Piazza, Monica Cavraro, Livio Trentin, Gianpietro Semenzato

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression. Patients and Methods According to time of stopping lenalidomide, patients were subdivided into 3 groups: early stop (ES) (n = 23), when therapy was discontinued within 6 months; intermediate (INT) (n = 23), when therapy was stopped between 7 to 24 months; and long survival (LS) (n = 45), when therapy was maintained for more than 2 years. The median age of the whole cohort was 70 years (range, 42-85 years); 40% had an International Staging System score of 2 or 3. Results High-risk cytogenetic findings, including 1q gain, was reported in 65% ES, 43% INT, and 21% LS. Overall response rate was 63%, with median progression-free survival and overall survival of 33 and 56 months, respectively. Conclusion Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28% of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.

Original languageEnglish
Pages (from-to)592-598
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Multiple Myeloma
Cytogenetics
Survival
Disease-Free Survival
Therapeutics
lenalidomide

Keywords

  • Continous treatment
  • Cytogenetic
  • Lenalidomide
  • Real life evaluation
  • Refractory-relapsed multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma : A Real-Life Evaluation. / Zambello, Renato; Bonaldi, Laura; Berno, Tamara; Martines, Annalisa; Sechettin, Erica; De March, Elena; Branca, Antonio; Lico, Albana; Minotto, Claudia; Briani, Chiara; Gurrieri, Carmela; Temporin, Francesca; Battistutta, Claudia; Piazza, Francesco; Cavraro, Monica; Trentin, Livio; Semenzato, Gianpietro.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 10, 01.10.2015, p. 592-598.

Research output: Contribution to journalArticle

Zambello, R, Bonaldi, L, Berno, T, Martines, A, Sechettin, E, De March, E, Branca, A, Lico, A, Minotto, C, Briani, C, Gurrieri, C, Temporin, F, Battistutta, C, Piazza, F, Cavraro, M, Trentin, L & Semenzato, G 2015, 'Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation', Clinical Lymphoma, Myeloma and Leukemia, vol. 15, no. 10, pp. 592-598. https://doi.org/10.1016/j.clml.2015.05.003
Zambello, Renato ; Bonaldi, Laura ; Berno, Tamara ; Martines, Annalisa ; Sechettin, Erica ; De March, Elena ; Branca, Antonio ; Lico, Albana ; Minotto, Claudia ; Briani, Chiara ; Gurrieri, Carmela ; Temporin, Francesca ; Battistutta, Claudia ; Piazza, Francesco ; Cavraro, Monica ; Trentin, Livio ; Semenzato, Gianpietro. / Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma : A Real-Life Evaluation. In: Clinical Lymphoma, Myeloma and Leukemia. 2015 ; Vol. 15, No. 10. pp. 592-598.
@article{c385a71fb84f4e91958495da2499ea30,
title = "Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation",
abstract = "Introduction In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression. Patients and Methods According to time of stopping lenalidomide, patients were subdivided into 3 groups: early stop (ES) (n = 23), when therapy was discontinued within 6 months; intermediate (INT) (n = 23), when therapy was stopped between 7 to 24 months; and long survival (LS) (n = 45), when therapy was maintained for more than 2 years. The median age of the whole cohort was 70 years (range, 42-85 years); 40{\%} had an International Staging System score of 2 or 3. Results High-risk cytogenetic findings, including 1q gain, was reported in 65{\%} ES, 43{\%} INT, and 21{\%} LS. Overall response rate was 63{\%}, with median progression-free survival and overall survival of 33 and 56 months, respectively. Conclusion Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28{\%} of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.",
keywords = "Continous treatment, Cytogenetic, Lenalidomide, Real life evaluation, Refractory-relapsed multiple myeloma",
author = "Renato Zambello and Laura Bonaldi and Tamara Berno and Annalisa Martines and Erica Sechettin and {De March}, Elena and Antonio Branca and Albana Lico and Claudia Minotto and Chiara Briani and Carmela Gurrieri and Francesca Temporin and Claudia Battistutta and Francesco Piazza and Monica Cavraro and Livio Trentin and Gianpietro Semenzato",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.clml.2015.05.003",
language = "English",
volume = "15",
pages = "592--598",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "10",

}

TY - JOUR

T1 - Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma

T2 - A Real-Life Evaluation

AU - Zambello, Renato

AU - Bonaldi, Laura

AU - Berno, Tamara

AU - Martines, Annalisa

AU - Sechettin, Erica

AU - De March, Elena

AU - Branca, Antonio

AU - Lico, Albana

AU - Minotto, Claudia

AU - Briani, Chiara

AU - Gurrieri, Carmela

AU - Temporin, Francesca

AU - Battistutta, Claudia

AU - Piazza, Francesco

AU - Cavraro, Monica

AU - Trentin, Livio

AU - Semenzato, Gianpietro

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Introduction In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression. Patients and Methods According to time of stopping lenalidomide, patients were subdivided into 3 groups: early stop (ES) (n = 23), when therapy was discontinued within 6 months; intermediate (INT) (n = 23), when therapy was stopped between 7 to 24 months; and long survival (LS) (n = 45), when therapy was maintained for more than 2 years. The median age of the whole cohort was 70 years (range, 42-85 years); 40% had an International Staging System score of 2 or 3. Results High-risk cytogenetic findings, including 1q gain, was reported in 65% ES, 43% INT, and 21% LS. Overall response rate was 63%, with median progression-free survival and overall survival of 33 and 56 months, respectively. Conclusion Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28% of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.

AB - Introduction In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression. Patients and Methods According to time of stopping lenalidomide, patients were subdivided into 3 groups: early stop (ES) (n = 23), when therapy was discontinued within 6 months; intermediate (INT) (n = 23), when therapy was stopped between 7 to 24 months; and long survival (LS) (n = 45), when therapy was maintained for more than 2 years. The median age of the whole cohort was 70 years (range, 42-85 years); 40% had an International Staging System score of 2 or 3. Results High-risk cytogenetic findings, including 1q gain, was reported in 65% ES, 43% INT, and 21% LS. Overall response rate was 63%, with median progression-free survival and overall survival of 33 and 56 months, respectively. Conclusion Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28% of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.

KW - Continous treatment

KW - Cytogenetic

KW - Lenalidomide

KW - Real life evaluation

KW - Refractory-relapsed multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84942824578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942824578&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2015.05.003

DO - 10.1016/j.clml.2015.05.003

M3 - Article

C2 - 26141212

AN - SCOPUS:84942824578

VL - 15

SP - 592

EP - 598

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 10

ER -